Sponsored Content
In this special series, Tom Johnson, owner of TJ BioTech, tackles questions about optimizing trunk-injection applications to treat HLB.
Q: How is ReMedium TI® performing in the fight against citrus greening?
Tom Johnson: The reported overall performance of ReMedium TI® has been stellar over the last two years. The reports from the second year of injections are just starting to come in, but the harvest reports from the first injection year (2023–24 harvest) are extremely good.
Reports from around the Florida citrus-growing region are excellent and include results such as:
- 70 acres of 6- to 9-year-old Hamlins: 2022–23 production of 8,926 boxes increased 55% to 13,837 boxes in 2023–24.
- 49 acres of mostly 8- to 9-year-old Valencias (about 10% young replacements): 2022–23 production of 1,492 boxes increased 329% to 6,408 boxes in 2023–24.
- 30 acres of 10+ year-old Valencias: 2022–23 production of 2,657 boxes increased 51% to 4,022 boxes.
The ReMedium TI® was injected at the label rate using FLexInject® as the injection device.
The above numbers are real-world increases that are producing significant return on investment. The year-over-year comparison is a great visual tool to determine a turning point in the impact of citrus greening. Growers that are utilizing label rates of ReMedium TI® are reporting these kinds of results across the board, and the results speak to the importance of the purity of water, the purity of active ingredient and the use of FLexInject® to protect the oxytetracycline from heat and ultraviolet light degradation.
The reports that are just beginning to come in from the 2024–25 harvest seem to be equally as exciting. I will keep you posted as the harvest progresses.
Tom Johnson is the owner of TJ BioTech, the manufacturer of ReMedium TI®. If you have a question about trunk injection, please send it to citrusindustry@agnetmedia.com.
Share this Post
Sponsored Content